We are all dreamers.
Release time:
2020-07-15
sends off the busy 2019 year and ushers in a brand new 2020 year. Looking back on 2019 , I was touched too much, warmed too much, regretted too much, and looked forward to too much. This year, there are always some lost will let oneself unprepared, there is always some warmth let oneself like spring breeze. The lost things make me mature, and the warm things bring me new expectations. Spring to winter, four seasons cycle, day after day, year after year. 2018 seems to be yesterday, 2019 is history.
2020 means that we are entering the 1920 s. Standing at a new starting point in history, what should we do? In his New Year's message, President Xi pointed out the direction for us: seize the day and live up to our youth. President Xi's New Year message contains warmth and confidence, showing extraordinary Chinese style and Chinese strength. 2020 was a landmark year. China will build a moderately prosperous society and achieve the first centenary goal. "Belt and Road " initiative is a great project to connect people and cultures of all countries and promote exchanges in various fields. I am very fortunate to live in such a splendid China, and I am proud and proud to live in this new era. We should cherish every minute and second of the good time now, strive for progress, and live up to this beautiful era.
After I was 70 , all my female compatriots of the same age left their jobs and retired. However, our male compatriots are still struggling in their jobs, working and learning. I think the work is to do a line of love, based on the post, down-to-earth. Constantly recharge yourself at work, abandon the simple "cramming " indoctrination education, learn new knowledge with new methods, new media, and new environments, reserve for yourself, and ensure that you are at work Handy. Take learning as a work responsibility, a spiritual pursuit and a way of life. Learning by doing, learning by doing, preserving the spirit of striving for success, and enhancing the sense of responsibility of starting a business.
This is an era of great rejuvenation of the Chinese nation. In this era, the Chinese are fulfilling the Chinese dream and their own personal dreams. This is an era of innovation. While we are fulfilling our dreams, we should all live out ourselves and self-confidence. We are all dreamers. (Hong Zhiwei)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31